Lori Taylor
Vice President, Global Program Leader at Annexon Bioscience Inc - South San Francisco, CA, US
Lori Taylor's Colleagues at Annexon Bioscience Inc
Charles LaPree
Senior Vice President - Head of Global Regulatory Affairs and Quality Assurance
Lori Taylor's Contact Details
650-822-5500
Annexon Bioscience Inc
Lori Taylor's Company Details
Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye. The company's pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio. For more information, visit www.annexonbio.com.